1
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, March 31, 1998: US05733925 (479 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


2
Lawrence L Kunz, Richard A Klein, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, November 9, 1999: US05981568 (352 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


3
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NoeRx Corporation, Schwegman Lundberg Woessner & Kluth P A, June 13, 2000: US06074659 (263 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


4
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, September 22, 1998: US05811447 (221 worldwide citation)

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


5
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundbereg Woessner & Kluth P A, December 10, 2002: US06491938 (112 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


6
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, October 23, 2001: US06306421 (109 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


7
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, May 27, 2003: US06569441 (109 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


8
Lawrence L Kunz, Richard A Klein, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. SciMed Life Systems, Pennie & Edmonds, April 13, 2004: US06720350 (108 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


9
Lawrence L Kunz, John M Reno: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, December 16, 2003: US06663881 (91 worldwide citation)

Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a ...


10
Alton C Morgan Jr, Ananthachari Srinivasan, John M Reno, Alan R Fritzberg, David C Anderson: Antibody conjugates. NeoRx Corporation, Seed and Berry, April 21, 1992: US05106951 (65 worldwide citation)

There is disclosed an antibody and antibody-drug conjugate for targeting drug delivery as well as a class of chemicals, termed a drug-binding molecule of complementary structure (csDBM). The csDBM is designed to "fit" the drug by combining multiple non-covalent interactions between functional groups ...